<DOC>
	<DOCNO>NCT01010789</DOCNO>
	<brief_summary>The purpose research study study effectiveness , tolerability safety armodafinil outpatient binge eat disorder .</brief_summary>
	<brief_title>Armodafinil Binge Eating Disorder ( BED )</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Feeding Eating Disorders</mesh_term>
	<mesh_term>Binge-Eating Disorder</mesh_term>
	<mesh_term>Bulimia</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>Criteria enter study include follow : 1 . Subjects meet DSMIVTR criterion diagnosis binge eat disorder ( BED ) least last 6 month . The DSMIVTR criterion follow : 1 . Recurrent episodes binge eat . An episode binge eat characterize following : eating , discrete period time ( e.g. , within two hour period ) , amount food definitely large people would eat similar period time similar condition ; sense lack control eat episode ( e.g. , feel one stop eat control much one eating ) . 2 . The binge eat episode associate least three follow : eat much rapidly normal ; eat uncomfortably full ; eat large amount food feeling physically hungry ; eat alone embarrass much one eating ; feel disgust oneself , depress , feel guilty overeating . 3 . Marked distress regard binge eating . 4 . The binge eating occur , average , least two day week six month . 5 . The episodes binge eat occur exclusively course bulimia nervosa anorexia nervosa . 2 . In addition , subject report least 3 binge eating day per week 2 week prior randomization prospectively document takehome binge diary . A binge eat day ( binge day ) day least one binge eat episode occurs . 3 . Subjects BMI â‰¥ 25 . The subject population expect include overweight obese individual . 4 . Men woman , age 18 65 year , inclusive . 1 . Have concurrent symptom bulimia nervosa anorexia nervosa . 2 . Women pregnant , lactating , childbearing potential use adequate contraceptive measure . All female subject still uterus negative pregnancy test prior randomization . 3 . Subjects display clinically significant suicidality homicidality . 4 . Subjects begin new psychological ( e.g. , supportive psychotherapy , cognitive behavior therapy , interpersonal therapy ) weight loss ( e.g. , Weight Watchers , Overeaters Anonymous ) intervention within 3 month study entry . Subjects receive psychotherapy initiate prior 3 month begin study allow continue receive psychotherapy trial agree make change frequency nature psychotherapy course drug trial . 5 . A DSMIVTR diagnosis substance abuse dependence ( except nicotine abuse dependence ) within 6 month prior randomization . 6 . A lifetime DSMIVTR history psychosis , mania hypomania , dementia . 7 . History psychiatric personality disorder ( eg , schizotypal borderline ) might interfere diagnostic assessment , treatment , compliance . 8 . Clinically unstable medical disease , include cardiovascular , hepatic , renal , gastrointestinal , pulmonary , metabolic , endocrine systemic disease could interfere diagnosis , treatment , assessment BED . Subjects biochemically euthyroid enter study . 9 . Have history major cardiovascular event past 6 month , include unstable angina , acute myocardial infarction , coronary angioplasty , stroke . 10 . History seizure , include clinically febrile seizure childhood . 11 . Have uncontrolled hypertension ( &gt; 160/100 ) tachycardia ( heart rate &gt; 110 ) . 12 . Have ECG significant arrhythmias conduction abnormality , opinion physician investigator preclude study participation . 13 . Have clinically relevant abnormal laboratory result , specifically include hypokalemia . 14 . Subjects know allergy armodafinil . 15 . Subjects require treatment drug might interact adversely obscure action study medication . This include warfarin , anticonvulsant , clonidine , theophylline , pseudoephedrine . 16 . Subjects receive psychotropic medication ( hypnotic ) within four week prior randomization , include monoamine oxidase inhibitor , tricyclic , selective serotonin reuptake inhibitor , antipsychotic , mood stabilizer , psychostimulants . 17 . Subjects receive investigational medication depot neuroleptic within three month prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>